| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022331348 |
| P356 | DOI | 10.1007/BF00170946 |
| P698 | PubMed publication ID | 1335044 |
| P2093 | author name string | J. Hanson | |
| E. S. Johnson | |||
| R. C. Urtasun | |||
| D. Huyser-Wierenga | |||
| D. S. Fulton | |||
| B. Curry | |||
| M. Feldstein | |||
| B. Mielke | |||
| Huyser-Wierenga D | |||
| I. Scott-Brown | |||
| Scott-Brown I | |||
| P2860 | cites work | Stereotaxic irradiation of brain tumors | Q33890154 |
| Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. | Q40269521 | ||
| An analysis of dose-effect relationship in the radiotherapy of malignant gliomas | Q40285820 | ||
| High dose radiation therapy in the treatment of malignant gliomas: Final Report | Q40285828 | ||
| Dose, time and fractionation: A clinical hypothesis | Q41524871 | ||
| Cell Cycle Redistribution as a Factor in Multifraction Irradiation | Q41971590 | ||
| Multiple daily fractionated radiation therapy and misonidazole in the management of malignant astrocytoma. A preliminary report | Q43959088 | ||
| Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report | Q46364938 | ||
| A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study | Q48294502 | ||
| Misonidazole combined with hyperfractionation in the management of malignant glioma | Q48632169 | ||
| Super fractionation in glioblastoma multiforme-results of a phase II study | Q48892731 | ||
| Superfractionation: its rationale and anticipated benefits. | Q52434296 | ||
| Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. | Q55483140 | ||
| Selection bias in clinical trials of anaplastic glioma. | Q55485061 | ||
| Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial | Q55489648 | ||
| Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships | Q70372719 | ||
| Hyperfractionation | Q70543682 | ||
| A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES | Q78539166 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | radiotherapy dosage | Q71516412 |
| P304 | page(s) | 63-72 | |
| P577 | publication date | 1992-09-01 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study | |
| P478 | volume | 14 |
| Q39613251 | Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy |
| Q30417964 | Bionanotechnology and the future of glioma |
| Q35855352 | Canadian recommendations for the treatment of glioblastoma multiforme. |
| Q30794250 | Clinical review of the japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams |
| Q34480122 | Conformal radiotherapy for brain tumors |
| Q48421519 | Continuous hyperfractionated accelerated radiotherapy in the treatment of high-grade astrocytomas |
| Q38230650 | Current evidence of temozolomide and bevacizumab in treatment of gliomas. |
| Q41611838 | Current perspectives in gliomas |
| Q34149106 | Cyclooxygenase-2 modulates brain inflammation-related gene expression in central nervous system radiation injury |
| Q41482096 | Hyperfractionation: where do we stand? |
| Q46857246 | Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma |
| Q37533670 | Pediatric brain tumors: current treatment strategies and future therapeutic approaches |
| Q39208269 | Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. |
| Q43991256 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas |
| Q72054576 | Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme |
| Q41131710 | Recent trends in the radiotherapy of pediatric gliomas |
| Q43742085 | Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas |
| Q48220336 | TNF alpha and IL-1beta mediate intercellular adhesion molecule-1 induction via microglia-astrocyte interaction in CNS radiation injury |
| Q30605562 | Target volumes in radiotherapy for high-grade malignant glioma of the brain. |
| Q41470369 | The rationale and requirements for the development of boron neutron capture therapy of brain tumors |
| Q37724213 | Treatment of posterior fossa tumors in children |